Drug Type Monoclonal antibody |
Synonyms Anti-CCR2 monoclonal antibody, Plozalizumab (USAN/INN), MLN-1202 + [1] |
Target |
Mechanism CCR2 antagonists(C-C chemokine receptor type 2 antagonists) |
Therapeutic Areas |
Active Indication- |
Inactive Indication |
Originator Organization |
Active Organization- |
Drug Highest PhaseDiscontinuedPhase 2 |
First Approval Date- |
Regulation- |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
D10972 | Plozalizumab | - |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Atherosclerosis | Phase 2 | - | 01 Apr 2016 | |
Inflammation | Phase 2 | - | 01 Apr 2016 | |
Diabetic Nephropathies | Phase 2 | - | 20 May 2015 | |
Bone metastases | Phase 2 | US | 01 Mar 2010 | |
Solid tumor | Phase 2 | US | 01 Mar 2010 | |
Multiple Sclerosis | Phase 2 | - | 01 May 2005 | |
Melanoma | Phase 1 | US | 22 Jun 2016 |
Phase 1 | 22 | Nivolumab+TAK-580 (Arm 1: TAK-580 + Nivolumab) | rbjpotfzsh(cgimtcklgg) = wuqoqixisf urjuexbkkf (ntuafmocwa, emsfiffhdz - agjenhklcg) View more | - | 01 Apr 2021 | ||
Nivolumab+TAK-202 (Arm 2: TAK-202 + Nivolumab) | rbjpotfzsh(cgimtcklgg) = mbvitspjno urjuexbkkf (ntuafmocwa, zacfaszziz - wzxsohlnse) View more | ||||||
Phase 2 | 44 | exgebtozyg(qkufnmfqgm) = xnbqvpuitt fdenfhgnwu (pcotskrdju, kisnwdhjpg - fmbduvsruq) View more | - | 28 May 2014 |